• Jerzy Hohendorff, Leszek Czupryniak, Grzegorz Dzida, Piotr Fichna, Przemyslawa Jarosz-Chobot, Tomasz Klupa, Malgorzata Mysliwiec, Agnieszka Szadkowska, Dorota A Zozulinska-Ziolkiewicz, and Maciej T Malecki.
• Department of Metabolic Diseases, Jagiellonian University Medical College, Krakow, Poland.
• Arch Med Sci. 2023 Jan 1; 19 (3): 757764757-764.

AbstractStandard markers of glycaemic control, such as glycated haemoglobin (HbA1c) and self-measurement of blood glucose (SMBG), have proven insufficient. HbA1c is an averaged measurement that does not give information about glucose variability. SMBG provides limited, intermittent blood glucose (BG) values over the day and is associated with poor compliance because of the invasiveness of the method and social discomfort. In contrast to glucometers, continuous glucose monitoring (CGM) devices do not require finger-stick blood samples, but instead measure BG via percutaneous or subcutaneous sensors. The immediate benefits of CGM include prevention of hypoglycaemia or hyperglycaemia, and automated analysis of long-term glycaemic data enables reliable treatment adjustments. This review describes the principles of CGM and how CGM data have changed diabetes treatment standards by introducing new glycaemic control parameters. It also compares different CGM devices and examines how the convenience of sharing CGM data in telehealth applies to the current coronavirus-19 pandemic.Copyright: © 2021 Termedia & Banach.

3 keywords...

hide…